David Barton
Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Viral | 41 | 2025 | 693 | 6.700 |
Why?
| | Poliovirus | 31 | 2025 | 85 | 5.680 |
Why?
| | Brain Injuries, Traumatic | 9 | 2025 | 400 | 3.040 |
Why?
| | Virus Replication | 19 | 2025 | 532 | 2.950 |
Why?
| | Viral Proteins | 12 | 2025 | 369 | 2.590 |
Why?
| | Endoribonucleases | 9 | 2014 | 79 | 2.200 |
Why?
| | Recombination, Genetic | 4 | 2025 | 206 | 1.900 |
Why?
| | HeLa Cells | 28 | 2020 | 640 | 1.450 |
Why?
| | Picornaviridae | 3 | 2020 | 20 | 1.390 |
Why?
| | Ribavirin | 3 | 2020 | 82 | 1.230 |
Why?
| | Enterovirus C, Human | 2 | 2025 | 3 | 1.230 |
Why?
| | Snake Bites | 2 | 2019 | 23 | 1.170 |
Why?
| | Blepharoptosis | 1 | 2025 | 12 | 0.910 |
Why?
| | Blood-Brain Barrier | 2 | 2024 | 144 | 0.900 |
Why?
| | Multiple Organ Failure | 1 | 2025 | 127 | 0.880 |
Why?
| | Viral Nonstructural Proteins | 3 | 2020 | 67 | 0.850 |
Why?
| | Hepacivirus | 6 | 2014 | 238 | 0.840 |
Why?
| | Polyadenylation | 2 | 2015 | 42 | 0.820 |
Why?
| | Agkistrodon | 2 | 2023 | 6 | 0.790 |
Why?
| | Nucleic Acid Conformation | 11 | 2010 | 725 | 0.780 |
Why?
| | Emergency Medical Services | 2 | 2023 | 647 | 0.780 |
Why?
| | Air Ambulances | 1 | 2023 | 40 | 0.770 |
Why?
| | Sinusitis | 1 | 2025 | 239 | 0.730 |
Why?
| | RNA | 5 | 2020 | 930 | 0.690 |
Why?
| | Drug Resistance, Viral | 3 | 2020 | 120 | 0.680 |
Why?
| | Murine hepatitis virus | 1 | 2020 | 16 | 0.670 |
Why?
| | Protein Biosynthesis | 12 | 2008 | 444 | 0.650 |
Why?
| | Antiviral Agents | 5 | 2020 | 747 | 0.630 |
Why?
| | Hypogonadism | 2 | 2020 | 92 | 0.630 |
Why?
| | Heart Arrest | 1 | 2024 | 385 | 0.620 |
Why?
| | Hydrocortisone | 1 | 2021 | 316 | 0.610 |
Why?
| | Coral Snakes | 1 | 2019 | 3 | 0.600 |
Why?
| | RNA, Messenger | 7 | 2008 | 2828 | 0.600 |
Why?
| | Bupivacaine | 1 | 2018 | 38 | 0.570 |
Why?
| | Polyribosomes | 2 | 2008 | 24 | 0.570 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2746 | 0.530 |
Why?
| | Nerve Block | 1 | 2018 | 97 | 0.520 |
Why?
| | Amino Acid Substitution | 5 | 2020 | 310 | 0.520 |
Why?
| | RNA Stability | 4 | 2014 | 116 | 0.500 |
Why?
| | Viral Core Proteins | 3 | 2003 | 22 | 0.500 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1597 | 0.500 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 403 | 0.490 |
Why?
| | Base Sequence | 14 | 2012 | 2180 | 0.490 |
Why?
| | Leucine | 1 | 2016 | 116 | 0.480 |
Why?
| | Humans | 56 | 2025 | 141187 | 0.440 |
Why?
| | Ribonuclease, Pancreatic | 1 | 2014 | 12 | 0.430 |
Why?
| | RNA Cleavage | 1 | 2014 | 10 | 0.430 |
Why?
| | Templates, Genetic | 3 | 2010 | 63 | 0.420 |
Why?
| | Influenza A virus | 1 | 2014 | 111 | 0.420 |
Why?
| | Neurofilament Proteins | 2 | 2024 | 62 | 0.420 |
Why?
| | Wounds and Injuries | 3 | 2025 | 891 | 0.410 |
Why?
| | DNA-Directed RNA Polymerases | 3 | 2020 | 63 | 0.400 |
Why?
| | Molecular Sequence Data | 11 | 2012 | 2929 | 0.390 |
Why?
| | Pain | 1 | 2018 | 781 | 0.390 |
Why?
| | Transcription, Genetic | 7 | 2015 | 1487 | 0.390 |
Why?
| | Biomarkers | 4 | 2025 | 4174 | 0.390 |
Why?
| | Uridine | 2 | 2009 | 30 | 0.390 |
Why?
| | Poly U | 2 | 2010 | 4 | 0.370 |
Why?
| | Genome, Viral | 5 | 2025 | 223 | 0.360 |
Why?
| | Poly A | 2 | 2010 | 52 | 0.360 |
Why?
| | Host-Pathogen Interactions | 1 | 2014 | 372 | 0.350 |
Why?
| | Conserved Sequence | 2 | 2008 | 238 | 0.340 |
Why?
| | Cysteine Endopeptidases | 2 | 2008 | 74 | 0.340 |
Why?
| | Young Adult | 9 | 2025 | 13673 | 0.330 |
Why?
| | Ribosomes | 2 | 2004 | 186 | 0.330 |
Why?
| | Poly C | 2 | 2008 | 4 | 0.330 |
Why?
| | Open Reading Frames | 2 | 2008 | 132 | 0.320 |
Why?
| | Deoxycytosine Nucleotides | 1 | 2009 | 13 | 0.310 |
Why?
| | Mutation | 9 | 2020 | 4013 | 0.310 |
Why?
| | Enterovirus | 2 | 2012 | 85 | 0.300 |
Why?
| | Male | 19 | 2025 | 69783 | 0.290 |
Why?
| | Alcohol Drinking | 1 | 2016 | 834 | 0.290 |
Why?
| | Glasgow Outcome Scale | 2 | 2025 | 11 | 0.290 |
Why?
| | Eukaryotic Initiation Factor-4G | 1 | 2008 | 7 | 0.290 |
Why?
| | Adult | 14 | 2025 | 39177 | 0.290 |
Why?
| | Pain Management | 2 | 2025 | 396 | 0.280 |
Why?
| | Uridine Monophosphate | 2 | 2008 | 16 | 0.270 |
Why?
| | Base Composition | 1 | 2007 | 79 | 0.270 |
Why?
| | Dinucleoside Phosphates | 1 | 2007 | 30 | 0.270 |
Why?
| | Glasgow Coma Scale | 2 | 2024 | 203 | 0.260 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1116 | 0.250 |
Why?
| | Middle Aged | 11 | 2025 | 34434 | 0.240 |
Why?
| | Sufentanil | 1 | 2025 | 3 | 0.230 |
Why?
| | Mutagenesis, Site-Directed | 3 | 2016 | 377 | 0.230 |
Why?
| | Ribonucleases | 1 | 2004 | 48 | 0.220 |
Why?
| | Intracranial Hemorrhage, Traumatic | 1 | 2024 | 10 | 0.220 |
Why?
| | Aged | 9 | 2025 | 24574 | 0.210 |
Why?
| | Dendritic Spines | 2 | 2016 | 68 | 0.210 |
Why?
| | Kinetics | 5 | 2008 | 1652 | 0.210 |
Why?
| | Protein Binding | 5 | 2020 | 2239 | 0.210 |
Why?
| | RNA, Ribosomal | 3 | 2014 | 168 | 0.210 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 398 | 0.210 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 187 | 0.200 |
Why?
| | Opiate Substitution Treatment | 1 | 2025 | 166 | 0.200 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2025 | 184 | 0.200 |
Why?
| | Prospective Studies | 5 | 2025 | 7739 | 0.200 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2023 | 60 | 0.190 |
Why?
| | 5' Untranslated Regions | 4 | 2012 | 59 | 0.190 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 123 | 0.190 |
Why?
| | Anaphylaxis | 1 | 2023 | 107 | 0.180 |
Why?
| | Uridine Triphosphate | 1 | 2001 | 10 | 0.180 |
Why?
| | Cell-Free System | 5 | 2008 | 55 | 0.180 |
Why?
| | Trauma Centers | 1 | 2024 | 447 | 0.180 |
Why?
| | Hepatitis C | 1 | 2004 | 250 | 0.180 |
Why?
| | Buprenorphine | 1 | 2025 | 179 | 0.180 |
Why?
| | Protein Conformation | 3 | 2015 | 941 | 0.180 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.180 |
Why?
| | Animals | 12 | 2023 | 37657 | 0.170 |
Why?
| | Female | 10 | 2025 | 75515 | 0.170 |
Why?
| | Models, Molecular | 4 | 2015 | 1603 | 0.170 |
Why?
| | Plasmids | 4 | 2008 | 365 | 0.170 |
Why?
| | Nucleotide Motifs | 1 | 2020 | 36 | 0.170 |
Why?
| | Enterovirus B, Human | 1 | 2020 | 26 | 0.170 |
Why?
| | Computational Biology | 1 | 2025 | 661 | 0.160 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2024 | 326 | 0.160 |
Why?
| | Sindbis Virus | 2 | 1991 | 10 | 0.160 |
Why?
| | Carrier Proteins | 2 | 2009 | 740 | 0.160 |
Why?
| | Picornaviridae Infections | 1 | 2020 | 51 | 0.160 |
Why?
| | Pituitary Gland | 1 | 2020 | 150 | 0.150 |
Why?
| | Brain Injuries | 2 | 2016 | 502 | 0.150 |
Why?
| | Hypothalamus | 1 | 2020 | 155 | 0.150 |
Why?
| | Ribonuclease T1 | 2 | 2009 | 5 | 0.150 |
Why?
| | Injury Severity Score | 3 | 2024 | 559 | 0.150 |
Why?
| | Mutation, Missense | 2 | 2019 | 339 | 0.150 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2009 | 92 | 0.150 |
Why?
| | Fascia | 1 | 2018 | 17 | 0.150 |
Why?
| | Femoral Nerve | 1 | 2018 | 19 | 0.150 |
Why?
| | Guanidine | 3 | 2009 | 21 | 0.140 |
Why?
| | Apolipoprotein E4 | 1 | 2018 | 38 | 0.140 |
Why?
| | Injections | 1 | 2018 | 191 | 0.140 |
Why?
| | Cohort Studies | 3 | 2024 | 5799 | 0.140 |
Why?
| | Anesthetics, Local | 1 | 2018 | 101 | 0.140 |
Why?
| | Mice | 7 | 2020 | 18048 | 0.130 |
Why?
| | Amino Acid Sequence | 4 | 2008 | 2158 | 0.130 |
Why?
| | Opioid-Related Disorders | 1 | 2025 | 562 | 0.130 |
Why?
| | Mice, Inbred C57BL | 5 | 2020 | 5887 | 0.130 |
Why?
| | Models, Genetic | 3 | 2008 | 591 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2020 | 519 | 0.130 |
Why?
| | Neuropsychological Tests | 2 | 2024 | 1085 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2025 | 16273 | 0.120 |
Why?
| | Peptide Initiation Factors | 1 | 1996 | 16 | 0.120 |
Why?
| | Registries | 1 | 2024 | 2135 | 0.120 |
Why?
| | Alcohols | 1 | 2016 | 28 | 0.120 |
Why?
| | Nucleotides | 2 | 2008 | 127 | 0.120 |
Why?
| | Administration, Sublingual | 2 | 2025 | 12 | 0.120 |
Why?
| | Cell Line | 4 | 2014 | 2885 | 0.120 |
Why?
| | Binding, Competitive | 2 | 2008 | 196 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 1 | 2016 | 370 | 0.110 |
Why?
| | Time Factors | 5 | 2025 | 6956 | 0.110 |
Why?
| | Risk Assessment | 1 | 2024 | 3490 | 0.110 |
Why?
| | DNA, Complementary | 2 | 2008 | 274 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 5636 | 0.110 |
Why?
| | Hydrolysis | 1 | 2014 | 196 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1865 | 0.110 |
Why?
| | RNA Precursors | 1 | 1995 | 156 | 0.110 |
Why?
| | RNA, Small Nuclear | 1 | 2014 | 37 | 0.110 |
Why?
| | White Matter | 1 | 2016 | 147 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 330 | 0.100 |
Why?
| | Genetic Complementation Test | 3 | 2004 | 66 | 0.100 |
Why?
| | Sulfur Radioisotopes | 2 | 2008 | 15 | 0.100 |
Why?
| | RNA, Double-Stranded | 2 | 2004 | 59 | 0.100 |
Why?
| | Binding Sites | 2 | 2008 | 1316 | 0.100 |
Why?
| | Cells, Cultured | 1 | 2020 | 4208 | 0.100 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 859 | 0.100 |
Why?
| | Macrophages | 1 | 2020 | 1561 | 0.100 |
Why?
| | Testosterone | 1 | 2016 | 404 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3709 | 0.090 |
Why?
| | Autoantibodies | 1 | 2020 | 1470 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5200 | 0.090 |
Why?
| | Emergency Medical Technicians | 1 | 2012 | 41 | 0.090 |
Why?
| | Patient Care Management | 1 | 2012 | 56 | 0.090 |
Why?
| | Argonaute Proteins | 1 | 2012 | 27 | 0.090 |
Why?
| | West Nile virus | 1 | 2012 | 42 | 0.090 |
Why?
| | Adolescent | 5 | 2021 | 22007 | 0.090 |
Why?
| | Immune Evasion | 1 | 2012 | 63 | 0.090 |
Why?
| | West Nile Fever | 1 | 2012 | 53 | 0.090 |
Why?
| | Semliki forest virus | 1 | 1991 | 2 | 0.090 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2014 | 546 | 0.090 |
Why?
| | Interferon Type I | 1 | 2012 | 141 | 0.090 |
Why?
| | Alphavirus | 1 | 1991 | 22 | 0.090 |
Why?
| | Genes, Viral | 1 | 1991 | 92 | 0.090 |
Why?
| | Amyloid beta-Peptides | 1 | 2013 | 233 | 0.090 |
Why?
| | Physical Examination | 1 | 2012 | 241 | 0.090 |
Why?
| | Temperature | 3 | 2004 | 669 | 0.080 |
Why?
| | RNA, Untranslated | 1 | 2012 | 124 | 0.080 |
Why?
| | Logistic Models | 1 | 2016 | 2086 | 0.080 |
Why?
| | Cerebral Cortex | 1 | 2013 | 461 | 0.080 |
Why?
| | DNA Primers | 2 | 2004 | 510 | 0.080 |
Why?
| | Codon | 2 | 2007 | 92 | 0.080 |
Why?
| | Exoribonucleases | 1 | 2010 | 47 | 0.080 |
Why?
| | Mutagenesis | 2 | 2008 | 182 | 0.070 |
Why?
| | Uracil | 1 | 2008 | 30 | 0.070 |
Why?
| | Genes, Dominant | 1 | 2008 | 97 | 0.070 |
Why?
| | Base Pairing | 1 | 2008 | 64 | 0.070 |
Why?
| | Cytosine | 1 | 2008 | 48 | 0.070 |
Why?
| | Adenine Nucleotides | 1 | 2008 | 24 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2014 | 1110 | 0.070 |
Why?
| | Oligoribonucleotides | 1 | 2008 | 52 | 0.070 |
Why?
| | Puromycin | 2 | 1999 | 10 | 0.070 |
Why?
| | Cognition | 1 | 2016 | 1222 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2004 | 2064 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 149 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4073 | 0.070 |
Why?
| | Protein Processing, Post-Translational | 2 | 2008 | 464 | 0.070 |
Why?
| | RNA Caps | 2 | 2012 | 33 | 0.070 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2008 | 176 | 0.060 |
Why?
| | Depression | 1 | 2016 | 1483 | 0.060 |
Why?
| | Transdermal Patch | 1 | 2025 | 15 | 0.060 |
Why?
| | Administration, Cutaneous | 1 | 2025 | 128 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 689 | 0.060 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2005 | 99 | 0.060 |
Why?
| | Selection, Genetic | 1 | 2007 | 264 | 0.060 |
Why?
| | Sequence Deletion | 2 | 2004 | 183 | 0.060 |
Why?
| | Diffuse Axonal Injury | 1 | 2024 | 8 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2012 | 1122 | 0.050 |
Why?
| | Quality of Life | 1 | 2016 | 2999 | 0.050 |
Why?
| | Phylogeny | 1 | 2008 | 1018 | 0.050 |
Why?
| | Cytoplasm | 1 | 2004 | 273 | 0.050 |
Why?
| | Antivenins | 1 | 2023 | 28 | 0.050 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2023 | 59 | 0.050 |
Why?
| | Horses | 1 | 2023 | 198 | 0.050 |
Why?
| | Pain Measurement | 1 | 2025 | 554 | 0.050 |
Why?
| | Capsid | 1 | 2002 | 91 | 0.050 |
Why?
| | Craniocerebral Trauma | 2 | 2016 | 170 | 0.050 |
Why?
| | Patients | 1 | 2023 | 180 | 0.050 |
Why?
| | Poly G | 1 | 2001 | 2 | 0.050 |
Why?
| | Precipitin Tests | 1 | 2001 | 98 | 0.040 |
Why?
| | Risk Factors | 1 | 2016 | 10438 | 0.040 |
Why?
| | Medical Audit | 2 | 1991 | 78 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1828 | 0.040 |
Why?
| | Interferons | 1 | 2002 | 195 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2002 | 811 | 0.040 |
Why?
| | Anisomycin | 1 | 1999 | 2 | 0.040 |
Why?
| | Ricin | 1 | 1999 | 8 | 0.040 |
Why?
| | Cycloheximide | 1 | 1999 | 53 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 1999 | 18 | 0.040 |
Why?
| | Recovery of Function | 1 | 2024 | 678 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1999 | 47 | 0.040 |
Why?
| | Phosphorylation | 1 | 2024 | 1768 | 0.040 |
Why?
| | Diphtheria Toxin | 1 | 1999 | 65 | 0.040 |
Why?
| | Protein Domains | 1 | 2020 | 301 | 0.040 |
Why?
| | Apolipoprotein E3 | 1 | 2018 | 3 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2001 | 401 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2002 | 510 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2018 | 149 | 0.030 |
Why?
| | Inflammation | 2 | 2020 | 2890 | 0.030 |
Why?
| | Unconsciousness | 1 | 2016 | 21 | 0.030 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1996 | 25 | 0.030 |
Why?
| | Fluoresceins | 1 | 2016 | 49 | 0.030 |
Why?
| | Subcellular Fractions | 1 | 1996 | 78 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1996 | 86 | 0.030 |
Why?
| | Maze Learning | 1 | 2016 | 104 | 0.030 |
Why?
| | Indicators and Reagents | 1 | 1996 | 110 | 0.030 |
Why?
| | Cytidine Triphosphate | 1 | 1995 | 18 | 0.030 |
Why?
| | Guanidines | 1 | 1995 | 41 | 0.030 |
Why?
| | Golgi Apparatus | 1 | 2016 | 100 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2255 | 0.030 |
Why?
| | tau Proteins | 1 | 2016 | 94 | 0.030 |
Why?
| | Amyloid | 1 | 2016 | 96 | 0.030 |
Why?
| | Point Mutation | 1 | 1996 | 237 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 336 | 0.030 |
Why?
| | Immunoblotting | 1 | 1995 | 310 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1996 | 533 | 0.030 |
Why?
| | Methionine | 1 | 1995 | 159 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 1996 | 579 | 0.030 |
Why?
| | Autoimmunity | 1 | 2020 | 908 | 0.030 |
Why?
| | Peptides | 1 | 1999 | 978 | 0.030 |
Why?
| | Hospitals, Teaching | 2 | 1991 | 115 | 0.030 |
Why?
| | Dentate Gyrus | 1 | 2013 | 39 | 0.030 |
Why?
| | Coloring Agents | 1 | 2013 | 96 | 0.030 |
Why?
| | Azepines | 1 | 2013 | 97 | 0.020 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2013 | 79 | 0.020 |
Why?
| | Alanine | 1 | 2013 | 153 | 0.020 |
Why?
| | Poliomyelitis | 1 | 1993 | 37 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2180 | 0.020 |
Why?
| | District of Columbia | 1 | 2012 | 33 | 0.020 |
Why?
| | Functional Laterality | 1 | 2013 | 240 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2902 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1110 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1357 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2016 | 516 | 0.020 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2012 | 17 | 0.020 |
Why?
| | Ambulances | 1 | 2012 | 52 | 0.020 |
Why?
| | Rhinovirus | 1 | 2012 | 58 | 0.020 |
Why?
| | Octoxynol | 1 | 1991 | 13 | 0.020 |
Why?
| | Centrifugation, Density Gradient | 1 | 1991 | 40 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 855 | 0.020 |
Why?
| | Escherichia coli | 1 | 1996 | 838 | 0.020 |
Why?
| | Deoxycholic Acid | 1 | 1991 | 17 | 0.020 |
Why?
| | Methylation | 1 | 2012 | 230 | 0.020 |
Why?
| | Detergents | 1 | 1991 | 45 | 0.020 |
Why?
| | Virulence | 1 | 2012 | 268 | 0.020 |
Why?
| | DEAD Box Protein 58 | 1 | 2010 | 7 | 0.020 |
Why?
| | Solubility | 1 | 1991 | 245 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11120 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 854 | 0.020 |
Why?
| | DEAD-box RNA Helicases | 1 | 2010 | 78 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2010 | 385 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2010 | 215 | 0.020 |
Why?
| | Chick Embryo | 1 | 1988 | 133 | 0.020 |
Why?
| | Brain Concussion | 1 | 2016 | 580 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2010 | 397 | 0.020 |
Why?
| | Hippocampus | 1 | 2013 | 939 | 0.020 |
Why?
| | Hospital Mortality | 1 | 1991 | 924 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 601 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 1991 | 638 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4404 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2012 | 3068 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2010 | 852 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2010 | 1154 | 0.010 |
Why?
| | Fibroblasts | 1 | 1988 | 1020 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2010 | 3469 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 2002 | 226 | 0.010 |
Why?
| | Surface Properties | 1 | 2002 | 412 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 1991 | 2172 | 0.010 |
Why?
| | Brefeldin A | 1 | 1997 | 9 | 0.010 |
Why?
| | Oximes | 1 | 1997 | 24 | 0.010 |
Why?
| | Cyclopentanes | 1 | 1997 | 19 | 0.010 |
Why?
| | Genetic Techniques | 1 | 1997 | 67 | 0.010 |
Why?
| | Benzimidazoles | 1 | 1997 | 182 | 0.010 |
Why?
| | Sulfonamides | 1 | 1997 | 520 | 0.010 |
Why?
| | Reading Frames | 1 | 1992 | 3 | 0.010 |
Why?
| | Helper Viruses | 1 | 1992 | 3 | 0.010 |
Why?
| | Virion | 1 | 1992 | 113 | 0.010 |
Why?
| | England | 1 | 1991 | 108 | 0.010 |
Why?
| | Peer Review | 1 | 1991 | 50 | 0.010 |
Why?
| | Trauma Severity Indices | 1 | 1991 | 111 | 0.010 |
Why?
| | Transfection | 1 | 1992 | 943 | 0.010 |
Why?
| | United Kingdom | 1 | 1991 | 322 | 0.000 |
Why?
| | Aged, 80 and over | 2 | 1991 | 7856 | 0.000 |
Why?
| | Central Nervous System | 1 | 1991 | 265 | 0.000 |
Why?
| | Infant | 2 | 1991 | 9818 | 0.000 |
Why?
| | Survival Rate | 1 | 1991 | 1970 | 0.000 |
Why?
| | Child, Preschool | 2 | 1991 | 11457 | 0.000 |
Why?
| | Child | 2 | 1991 | 22308 | 0.000 |
Why?
|
|
Barton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|